Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMVT Immunovant	$15.24 +3.2%	$16.54	$12.72 ▼ $34.47	$2.60B	0.66	1.47 million shs	637,425 shs
KYMR Kymera Therapeutics	$39.51 +4.9%	$45.00	$19.44 ▼ $53.27	$2.57B	2.18	746,415 shs	574,564 shs
MOR MorphoSys	$18.96	$18.96	$4.18 ▼ $19.50	$2.86B	1.2	1.02 million shs	N/A
NAGE Niagen Bioscience	$10.35 +5.4%	$11.73	$2.81 ▼ $14.69	$825.41M	2.12	949,423 shs	685,053 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMVT Immunovant	-4.53%	-8.27%	-18.59%	+5.28%	-49.47%
KYMR Kymera Therapeutics	-7.24%	-13.70%	-15.29%	+21.00%	-9.07%
MOR MorphoSys	0.00%	0.00%	0.00%	0.00%	0.00%
NAGE Niagen Bioscience	+0.92%	+1.87%	-13.10%	+0.92%	+257.09%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IMVT Immunovant	2.2704 of 5 stars	4.4	0.0	0.0	0.0	2.4	1.7	0.0
KYMR Kymera Therapeutics	3.0053 of 5 stars	4.6	3.0	0.0	0.0	0.7	2.5	0.0
MOR MorphoSys	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NAGE Niagen Bioscience	1.3399 of 5 stars	3.5	0.0	0.0	0.0	2.0	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMVT Immunovant	2.83	Moderate Buy	$35.20	131.05% Upside
KYMR Kymera Therapeutics	3.10	Buy	$59.11	49.61% Upside
MOR MorphoSys	0.00	N/A	N/A	N/A
NAGE Niagen Bioscience	3.00	Buy	$13.42	29.66% Upside

Current Analyst Ratings Breakdown

Latest NAGE, MOR, IMVT, and KYMR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	IMVT Immunovant	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $37.00
8/12/2025	IMVT Immunovant	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$33.00 ➝ $30.00
8/11/2025	IMVT Immunovant	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/11/2025	NAGE Niagen Bioscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $12.00
7/30/2025	KYMR Kymera Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$60.00
7/28/2025	IMVT Immunovant	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$17.00 ➝ $18.00
7/15/2025	KYMR Kymera Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/10/2025	IMVT Immunovant	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold	$18.00
7/3/2025	KYMR Kymera Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$70.00
6/27/2025	KYMR Kymera Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$56.00 ➝ $53.00
6/26/2025	KYMR Kymera Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$59.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMVT Immunovant	N/A	N/A	N/A	N/A	$4.16 per share	N/A
KYMR Kymera Therapeutics	$47.07M	54.66	N/A	N/A	$12.90 per share	3.06
MOR MorphoSys	$238.28M	11.99	N/A	N/A	$0.35 per share	54.17
NAGE Niagen Bioscience	$99.60M	8.29	$0.06 per share	164.50	$0.60 per share	17.25

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMVT Immunovant	-$413.84M	-$2.74	N/A	N/A	N/A	N/A	-80.60%	-71.89%	8/12/2025 (Estimated)
KYMR Kymera Therapeutics	-$223.86M	-$3.10	N/A	N/A	N/A	-409.07%	-30.11%	-25.65%	10/30/2025 (Estimated)
MOR MorphoSys	-$205.35M	-$3.48	N/A	N/A	N/A	-226.79%	-694.31%	-22.55%	N/A
NAGE Niagen Bioscience	$8.55M	$0.21	49.29	∞	N/A	15.24%	23.12%	15.53%	N/A

Latest NAGE, MOR, IMVT, and KYMR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q1 2026	IMVT Immunovant	-$0.69	-$0.60	+$0.09	-$0.71	N/A	N/A
8/11/2025	Q2 2025	KYMR Kymera Therapeutics	-$0.83	-$0.95	-$0.12	-$0.95	$17.37 million	$11.48 million
8/6/2025	Q2 2025	NAGE Niagen Bioscience	$0.02	$0.04	+$0.02	$0.04	$28.55 million	$31.12 million
5/29/2025	Q4 2025	IMVT Immunovant	-$0.72	-$0.64	+$0.08	-$0.64	N/A	$0.16 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A
MOR MorphoSys	N/A	N/A	N/A	N/A	N/A
NAGE Niagen Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMVT Immunovant	N/A	11.16	11.16
KYMR Kymera Therapeutics	N/A	8.49	8.49
MOR MorphoSys	4.98	1.38	1.38
NAGE Niagen Bioscience	N/A	3.88	3.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMVT Immunovant	47.08%
KYMR Kymera Therapeutics	N/A
MOR MorphoSys	18.38%
NAGE Niagen Bioscience	15.41%

Insider Ownership

Company	Insider Ownership
IMVT Immunovant	1.80%
KYMR Kymera Therapeutics	16.01%
MOR MorphoSys	0.05%
NAGE Niagen Bioscience	9.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMVT Immunovant	120	171.07 million	167.99 million	Optionable
KYMR Kymera Therapeutics	170	65.12 million	54.69 million	Optionable
MOR MorphoSys	730	150.62 million	150.55 million	Not Optionable
NAGE Niagen Bioscience	120	79.75 million	72.26 million	N/A

NAGE, MOR, IMVT, and KYMR Headlines

Recent News About These Companies

Niagen Bioscience (NASDAQ:NAGE) Given New $12.00 Price Target at HC Wainwright

August 12 at 8:09 AM | marketbeat.com

Q2 EPS Forecast for Niagen Bioscience Increased by Analyst

August 12 at 4:08 AM | marketbeat.com

Roth Capital Raises Earnings Estimates for Niagen Bioscience

August 12 at 3:51 AM | americanbankingnews.com

Breaking Down Niagen Bioscience: 4 Analysts Share Their Views

August 11 at 6:32 PM | benzinga.com

Analysts Set Niagen Bioscience, Inc. (NASDAQ:NAGE) PT at $13.22

August 11 at 2:13 AM | americanbankingnews.com

Roth Capital Forecasts Weaker Earnings for Niagen Bioscience

August 10 at 2:31 AM | americanbankingnews.com

Roth Capital Cuts Earnings Estimates for Niagen Bioscience

August 9 at 8:09 AM | marketbeat.com

Niagen Bioscience (NASDAQ:NAGE) Shares Gap Up on Better-Than-Expected Earnings

August 9 at 2:16 AM | americanbankingnews.com

Earnings Beat: Niagen Bioscience, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

August 8, 2025 | finance.yahoo.com

Niagen Bioscience (NASDAQ:NAGE) Shares Gap Up Following Strong Earnings

August 8, 2025 | marketbeat.com

Niagen Bioscience, Inc. (NASDAQ:NAGE) Given Average Recommendation of "Buy" by Brokerages

August 8, 2025 | marketbeat.com

Niagen Bioscience Reports Strong Q2 Sales Growth

August 6, 2025 | msn.com

Niagen Bioscience Inc (NAGE) Q2 2025: Everything You Need To Know Ahead Of Earnings

August 6, 2025 | finance.yahoo.com

Niagen Bioscience: Q2 Earnings Snapshot

August 6, 2025 | timesunion.comT

Niagen Bioscience (NAGE) Q2 Earnings and Revenues Surpass Estimates

August 6, 2025 | zacks.com

Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year ...

August 6, 2025 | gurufocus.com

Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook

August 6, 2025 | businesswire.com

Examining the Future: Niagen Bioscience's Earnings Outlook

August 5, 2025 | benzinga.com

Niagen Bioscience to Present at Canaccord Genuity’s 45th Annual Growth Conference

August 4, 2025 | finance.yahoo.com

Niagen Bioscience to Present at Canaccord Genuity's 45th Annual Growth Conference

August 4, 2025 | businesswire.com

Niagen Bioscience (NASDAQ:NAGE) Cut to "Buy" at Wall Street Zen

August 3, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NAGE, MOR, IMVT, and KYMR Company Descriptions

Immunovant NASDAQ:IMVT

$15.24 +0.48 (+3.22%)

As of 03:18 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Kymera Therapeutics NASDAQ:KYMR

$39.51 +1.83 (+4.86%)

As of 03:18 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

MorphoSys NASDAQ:MOR

$18.96 0.00 (0.00%)

As of 08/11/2025

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

Niagen Bioscience NASDAQ:NAGE

$10.35 +0.53 (+5.40%)

As of 02:57 PM Eastern

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time